Astellus Pharma

Astellas Pharma is a leading global pharmaceutical company headquartered in Tokyo, Japan, formed in 2005 through the merger of Yamanouchi and Fujisawa Pharmaceutical. The company focuses on turning innovative science into value for patients, particularly in oncology, urology, immunology, and nephrology. Astellas has successfully transitioned its portfolio toward high-growth areas, highlighted by blockbuster products like Xtandi for prostate cancer and Padcev for urothelial cancer. Beyond small molecules, the company is aggressively investing in advanced modalities including cell and gene therapies and antibody-drug conjugates. Astellas operates with a global reach, maintaining significant R&D and manufacturing footprints across Asia, Europe, and the Americas.